Trial · NCT00739960
Safety Study of Abatacept to Treat Refractory Sarcoidosis
NCT00739960, Phase 2, Terminated, University of Chicago; results first posted 2020-03-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety Study of Abatacept to Treat Refractory Sarcoidosis. Trials, record NCT00739960. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00739960
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety Study of Abatacept to Treat Refractory Sarcoidosis
- NCT number
- NCT00739960
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- University of Chicago
- Conditions
- Sarcoidosis
- Interventions
- Abatacept
- First posted
- 2008-08-22
- Last updated
- 2020-03-23
- Results first posted
- 2020-03-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of Abatacept in Progressive Pulmonary Sarcoidosis. | 24 weeks and 52 weeks | Adverse events that are considered by the investigator to be reasonably or probably related to Abatacept. |
| Secondary | Change From Baseline in 6-minute Walk Distance. | 24 weeks and 52 weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety of Abatacept in Progressive Pulmonary Sarcoidosis. | 24 weeks and 52 weeks | Since this study was designed to be a safety study, we chose safety as the primary outcome. Any change of symptoms from baseline was considered possibly related to the study drug, although unlikely. The study was discontinued due to funding withdrawal caused by the principal investigator switching institutions. | participant adverse events | NUMBER |
| SECONDARY | Change From Baseline in 6-minute Walk Distance. | 24 weeks and 52 weeks | Data was not collected for this Outcome Measure. |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety of Abatacept in Progressive Pulmonary Sarcoidosis. | Abatacept | 1 | participant adverse events |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Abatacept | 1 | |
| Overall Study | COMPLETED | Abatacept | 1 | |
| Overall Study | NOT COMPLETED | Abatacept | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Worsening shortness of breath | Respiratory, thoracic and mediastinal disorders | Abatacept | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Abatacept | ||
| Total, other adverse events | Abatacept | 1 | 1 |
| Total, serious adverse events | Abatacept | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00739960
GET https://conductscience.org/api/trials/v1/NCT00739960/registered